[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie (ABBV) shares rallied sharply on Monday after the pharmaceutical behemoth announced a definitive agreement to acquire Apogee Therapeutics (APGE) for about $10.9 billion.

The all-cash transaction will see ABBV purchase all outstanding APGE shares for just over $135 each, which translates to a 50% premium on their previous close. 

Fundamentals

See More
  • Market Capitalization, $K 1,037,873,920
  • Shares Outstanding, K 941,741
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 31,522 M
  • EBITDA $ 33,519 M
  • 60-Month Beta 0.53
  • Price/Sales 15.87
  • Price/Cash Flow 43.70
  • Price/Book 33.16

Options Overview Details

View History
  • Implied Volatility 34.26% (-0.48%)
  • Historical Volatility 28.73%
  • IV Percentile 37%
  • IV Rank 35.50%
  • IV High 47.67% on 07/30/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 2) 26.03 (2.35%)
  • Put/Call Vol Ratio 0.70
  • Today's Volume 27,201
  • Volume Avg (30-Day) 46,173
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 304,488
  • Open Int (30-Day) 358,916
  • Expected Range 1,081.05 to 1,133.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $9.01
  • Number of Estimates 6
  • High Estimate $9.26
  • Low Estimate $8.70
  • Prior Year $6.31
  • Growth Rate Est. (year over year) +42.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,052.15 +5.22%
on 06/02/26
1,182.73 -6.40%
on 06/08/26
+42.08 (+3.95%)
since 05/22/26
3-Month
850.51 +30.17%
on 04/29/26
1,182.73 -6.40%
on 06/08/26
+196.53 (+21.58%)
since 03/23/26
52-Week
623.78 +77.48%
on 08/08/25
1,182.73 -6.40%
on 06/08/26
+336.44 (+43.66%)
since 06/23/25

Most Recent Stories

More News
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 132.88 (+0.25%)
JNJ : 239.08 (+3.37%)
LLY : 1,107.08 (+0.45%)
ABBV : 234.76 (+2.07%)
REGN : 618.03 (+0.90%)
SNY : 41.60 (-0.43%)
Lilly declares third-quarter 2026 dividend

INDIANAPOLIS , June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common...

LLY : 1,107.08 (+0.45%)
3 Penny Stocks Under $5 Backed by Real Revenue Growth

These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside

LLY : 1,107.08 (+0.45%)
URG : 1.4100 (-1.40%)
GRAB : 3.46 (-0.86%)
ACRS : 4.92 (+1.65%)
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

TDOC : 7.69 (+1.45%)
NVO : 47.42 (+3.36%)
OZEM : 31.29 (+0.88%)
LLY : 1,107.08 (+0.45%)
DXCM : 68.92 (-0.22%)
OLLI : 72.79 (-0.86%)
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

HUM : 359.13 (-0.44%)
JNJ : 239.08 (+3.37%)
LLY : 1,107.08 (+0.45%)
DXCM : 68.92 (-0.22%)
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

INDIANAPOLIS , June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095)...

LLY : 1,107.08 (+0.45%)
These 3 Quality Stocks Will Make You Want to LEAP on Their Calls

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks...

SBUX : 101.05 (+0.90%)
NVO : 47.42 (+3.36%)
LLY : 1,107.08 (+0.45%)
PFE : 24.72 (-1.44%)
AMZN : 234.11 (+0.57%)
DIS : 103.53 (+1.05%)
Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable

In the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about it

LLY : 1,107.08 (+0.45%)
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the start

LLY : 1,107.08 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,169.13
2nd Resistance Point 1,145.57
1st Resistance Point 1,126.33
Last Price 1,107.08
1st Support Level 1,083.53
2nd Support Level 1,059.97
3rd Support Level 1,040.73

See More

52-Week High 1,182.73
Last Price 1,107.08
Fibonacci 61.8% 969.21
Fibonacci 50% 903.26
Fibonacci 38.2% 837.30
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.